Table 1 Baseline characteristics and rates of follow-up of stage 1 serological suspects, by site
From: Estimates of the duration of the early and late stage of gambiense sleeping sickness
Adjumani, Uganda | Arua, Uganda | Moyo, Uganda | Yumbe, Uganda | Kiri, s. Sudan | Maridi, s. Sudan | Total | |
|---|---|---|---|---|---|---|---|
Number of patients | 1140 | 2215 | 296 | 81 | 2201 | 730 | 6663 |
Baseline characteristics | |||||||
Median age (IQR) | 20 (12–32) | 25 (14–35) | 22 (12–36) | 25 (13–40) | 21 (13–32) | 23 (15–35) | 20 (12–33) |
Number female (%) | 595 (52.2) | 1148 (51.8) | 166 (56.1) | 44 (54.3) | 1231 (55.9) | 386 (52.8) | 3570 (53.6) |
Number screened actively (%) | 853 (74.8) | 1362 (61.5) | 239 (80.7) | 14 (17.3) | 926 (42.1) | 165 (22.6) | 3559 (53.4) |
Number with zero WBC in CSF† (%) | 607 (53.2) | 1027 (46.4) | 194 (65.5) | 21 (25.9) | 1052 (47.8) | 9 (0.02) | 2910 (43.7) |
Follow-up rates | |||||||
Not seen during follow-up (%) | 660 (57.9) | 410 (18.5) | 249 (84.1) | 47 (58.0) | 1502 (68.2) | 617 (84.5) | 3485 (52.3) |
Seen at least once (%) | 480 (42.1) | 1805 (81.5) | 47 (15.9) | 34 (42.0) | 699 (31.8) | 113 (15.5) | 3178 (47.7) |
Seen at 3 months (%) | 250 (21.9) | 1180 (53.3) | 23 (7.8) | 25 (30.9) | 412 (18.7) | 63 (8.6) | 1953 (29.3) |
Seen at 6 months (%) | 112 (9.8) | 570 (25.7) | 15 (2.1) | 11 (13.6) | 135 (6.1) | 15 (2.0) | 850 (12.8) |
Seen at 9 months (%) | 61 (5.3) | 299 (13.5) | 2 (0.7) | 4 (4.9) | 53 (2.4) | 11 (1.5) | 430 (6.5) |
Seen at 12 months (%) | 63 (5.5) | 366 (16.5) | 6 (2.0) | 6 (7.4) | 60 (2.7) | 9 (1.2) | 510 (7.6) |
Median person-days of observation†† (IQR) | 169 (98–277) | 177 (97–328) | 110 (97–201) | 151 (98–271) | 128 (96–209) | 117 (93–198) | 158 (97–281) |